Teriparatide as option for severe osteoporosis
We introduce an original study referring to Romanian population treated with teriparatide (TPT), an anabolic drug for severe menopausal, glucocorticoid and male hypogonadism-related osteoporosis. Primary end point is to analyze the parameters of persons who fulfilled the national criteria of TPT reg...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Amaltea Medical Publishing House
2016-12-01
|
| Series: | Romanian Journal of Medical Practice |
| Subjects: | |
| Online Access: | https://rjmp.com.ro/articles/2016.4/RJMP_2016_4_Art-10.pdf |
| _version_ | 1819123510123954176 |
|---|---|
| author | Mara CARSOTE Adina GHEMIGIAN Otilia RADU Ana VALEA |
| author_facet | Mara CARSOTE Adina GHEMIGIAN Otilia RADU Ana VALEA |
| author_sort | Mara CARSOTE |
| collection | DOAJ |
| description | We introduce an original study referring to Romanian population treated with teriparatide (TPT), an anabolic drug for severe menopausal, glucocorticoid and male hypogonadism-related osteoporosis. Primary end point is to analyze the parameters of persons who fulfilled the national criteria of TPT regarding co-morbidities and bone profile. Secondary end point is to reveal the skeleton indices 12 months after TPT (20 μg/day subcutaneous). Informed written consent was signed between July 2015 and June 2016. Out of 21 patients with a mean age of 66.76 years (yrs), except for 2 men, there were menopausal females with av. 21.47 yrs since menopause. 57% had a history of superior digestive condition, another 57% had a chronic thyroid disease and 29% had a non-thyroid autoimmune morbidity. 17 patients were pre-exposed to anti-osteoporotic drugs 4.23+/-3.49 yrs. Number of prevalent fractures was: 3.75+/-2.17 (median 3; min 1, max 9). 42% (N=9) of subjects were followed for 1 year: no new fracture was registered; each patient had at least one DXA site with a BMD (Bone Mineral Density) increase (mean T-score increase of the most affected region was of 0.56+/-0.2 SD); osteocalcin statistically significant elevated from 18.87+/4.22 ng/mL to 42.8+/-16.3 ng/mL (p<0.0005) while CrossLaps went from 0.46+/-0.22 ng/mL to 0.65+/-0.3 ng/mL (p=0.15). Early drop-offs were registered in 2 patients.
Based on this original study, patients with severe osteoporosis having a burden of many years of prior therapy or fragility fractures became candidates for TPT. After 12 months, the anabolic window was revealed by high bone remodelling blood markers, especially for osteocalcin. |
| first_indexed | 2024-12-22T07:09:29Z |
| format | Article |
| id | doaj.art-341619a59c794b56ac4be9d9662b399f |
| institution | Directory Open Access Journal |
| issn | 1842-8258 2069-6108 |
| language | English |
| last_indexed | 2024-12-22T07:09:29Z |
| publishDate | 2016-12-01 |
| publisher | Amaltea Medical Publishing House |
| record_format | Article |
| series | Romanian Journal of Medical Practice |
| spelling | doaj.art-341619a59c794b56ac4be9d9662b399f2022-12-21T18:34:33ZengAmaltea Medical Publishing HouseRomanian Journal of Medical Practice1842-82582069-61082016-12-0111434835410.37897/RJMP.2016.4.10Teriparatide as option for severe osteoporosisMara CARSOTE0Adina GHEMIGIAN1Otilia RADU2Ana VALEA3“C.I. Parhon” National Institute of Endocrinology; “Carol Davila” University of Medicine and Pharmacy, Bucharest“C.I. Parhon” National Institute of Endocrinology; “Carol Davila” University of Medicine and Pharmacy, Bucharest“Carol Davila” University of Medicine and Pharmacy, BucharestClinical County Hospital, “I. Hatieganu” University of Medicine and Pharmacy, Cluj-NapocaWe introduce an original study referring to Romanian population treated with teriparatide (TPT), an anabolic drug for severe menopausal, glucocorticoid and male hypogonadism-related osteoporosis. Primary end point is to analyze the parameters of persons who fulfilled the national criteria of TPT regarding co-morbidities and bone profile. Secondary end point is to reveal the skeleton indices 12 months after TPT (20 μg/day subcutaneous). Informed written consent was signed between July 2015 and June 2016. Out of 21 patients with a mean age of 66.76 years (yrs), except for 2 men, there were menopausal females with av. 21.47 yrs since menopause. 57% had a history of superior digestive condition, another 57% had a chronic thyroid disease and 29% had a non-thyroid autoimmune morbidity. 17 patients were pre-exposed to anti-osteoporotic drugs 4.23+/-3.49 yrs. Number of prevalent fractures was: 3.75+/-2.17 (median 3; min 1, max 9). 42% (N=9) of subjects were followed for 1 year: no new fracture was registered; each patient had at least one DXA site with a BMD (Bone Mineral Density) increase (mean T-score increase of the most affected region was of 0.56+/-0.2 SD); osteocalcin statistically significant elevated from 18.87+/4.22 ng/mL to 42.8+/-16.3 ng/mL (p<0.0005) while CrossLaps went from 0.46+/-0.22 ng/mL to 0.65+/-0.3 ng/mL (p=0.15). Early drop-offs were registered in 2 patients. Based on this original study, patients with severe osteoporosis having a burden of many years of prior therapy or fragility fractures became candidates for TPT. After 12 months, the anabolic window was revealed by high bone remodelling blood markers, especially for osteocalcin.https://rjmp.com.ro/articles/2016.4/RJMP_2016_4_Art-10.pdfteriparatideosteoporosisfragility fracture |
| spellingShingle | Mara CARSOTE Adina GHEMIGIAN Otilia RADU Ana VALEA Teriparatide as option for severe osteoporosis Romanian Journal of Medical Practice teriparatide osteoporosis fragility fracture |
| title | Teriparatide as option for severe osteoporosis |
| title_full | Teriparatide as option for severe osteoporosis |
| title_fullStr | Teriparatide as option for severe osteoporosis |
| title_full_unstemmed | Teriparatide as option for severe osteoporosis |
| title_short | Teriparatide as option for severe osteoporosis |
| title_sort | teriparatide as option for severe osteoporosis |
| topic | teriparatide osteoporosis fragility fracture |
| url | https://rjmp.com.ro/articles/2016.4/RJMP_2016_4_Art-10.pdf |
| work_keys_str_mv | AT maracarsote teriparatideasoptionforsevereosteoporosis AT adinaghemigian teriparatideasoptionforsevereosteoporosis AT otiliaradu teriparatideasoptionforsevereosteoporosis AT anavalea teriparatideasoptionforsevereosteoporosis |